Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
WuXi AppTec Co Ltd
SSE:603259
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (8), the stock would be worth CHf-44.45 (1 463% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.6 | CHf3.26 |
0%
|
| Industry Average | 8 | CHf-44.45 |
-1 463%
|
| Country Average | 12.7 | CHf-70.94 |
-2 276%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CH |
|
Molecular Partners AG
SIX:MOLN
|
122m CHF | -0.6 | -2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 14.6 | 88 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD | 12.6 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 21.3 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 43.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.2 |
| Median | 12.7 |
| 70th Percentile | 20.5 |
| Max | 1 129.6 |
Other Multiples
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
